What is HiberGene Diagnostics?
HiberGene Diagnostics operates as a premier ISO-certified developer and manufacturer of molecular diagnostics products. Based in Ireland, the company specializes in point-of-care and near-patient testing, effectively challenging traditional, time-intensive laboratory workflows. By integrating multidisciplinary expertise, HiberGene delivers high-throughput solutions that prioritize speed and accuracy. Their core value proposition lies in the end-to-end management of the product lifecycle, from initial design and development to manufacturing and global commercialization, ensuring that clinical providers receive reliable, high-quality diagnostic tools.
How much funding has HiberGene Diagnostics raised?
HiberGene Diagnostics has raised a total of $7.7M across 2 funding rounds:
Series A
$2.3M
Series B
$5.5M
Series A (2015): $2.3M with participation from Kernel Capital and Enterprise Ireland
Series B (2017): $5.5M led by Kernel Capital and Cantor Fitzgerald
Key Investors in HiberGene Diagnostics
Kernel Capital
Kernel Capital is a venture capital and private equity firm that specializes in investing in growth stage and early stage companies, providing both capital and strategic guidance to support scaling.
Enterprise Ireland
Enterprise Ireland is a government agency responsible for the development and growth of Irish businesses in the manufacturing and internationally traded services industries.
Cantor Fitzgerald
Cantor Fitzgerald is a global financial services firm providing institutional debt, equity sales, trading, investment banking, and real estate private equity services.
What's next for HiberGene Diagnostics?
With the support of its recent capital injection, HiberGene Diagnostics is well-positioned to scale its manufacturing capabilities and expand its footprint in the global diagnostics market. The strategic focus will likely center on accelerating the adoption of its point-of-care platforms, which are essential for modernizing patient care pathways. As the company moves into its next phase of growth, it will continue to leverage its robust intellectual property portfolio to address emerging challenges in molecular testing, potentially exploring new therapeutic areas or enhancing its existing high-throughput diagnostic suite to maintain its competitive edge in the healthcare technology sector.
See full HiberGene Diagnostics company page
